AnaMar AB, a privately held drug discovery company, is developing orally bioavailable, peripherally acting 5-HT2B receptor antagonists designed to prevent pathological fibrotic processes. The company is operative in discovery and the early phases of drug development, from the idea stage to clinical trials. This includes invention and optimization of new drug candidates, evaluation of preclinical efficacy and safety and finally, confirmatory early clinical studies in patients with fibrotic disease. The Candidate Drug AM1476, is in early clinical development.